Perioperative Bypassing Agent Therapy for Pulmonary Pleomorphic Carcinoma with Acquired Hemophilia

Ann Thorac Cardiovasc Surg. 2022 Aug 20;28(4):302-306. doi: 10.5761/atcs.cr.20-00257. Epub 2021 Jan 20.

Abstract

A 74-year-old man was admitted with lung cancer, and preoperative blood test showed abnormal activated partial thromboplastin time (APTT). Coagulation factor screening and APTT mixing test achieved a diagnosis of acquired hemophilia A (AHA). Bypassing agent therapy was indicated and lobectomy was successfully performed without bleeding complications. APTT returned to normal after the operation without any additional treatment for AHA. The pathogenesis of AHA is still unknown and there is no evidence for hemostatic strategy for AHA patients requiring surgery. This study supports the importance of hemostatic therapy and suggests that malignancy might cause AHA.

Keywords: acquired hemophilia; lung cancer; surgery.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Carcinoma*
  • Hemophilia A* / complications
  • Hemophilia A* / diagnosis
  • Hemophilia A* / drug therapy
  • Hemostatics*
  • Humans
  • Lung Neoplasms* / complications
  • Lung Neoplasms* / diagnostic imaging
  • Lung Neoplasms* / surgery
  • Male
  • Treatment Outcome

Substances

  • Hemostatics